CSPC Megalith Biopharmaceutical Co.,Ltd. Drug Pipeline

CSPC Megalith Biopharmaceutical Co.,Ltd. maintains a focused clinical development portfolio, with 20 trials registered since 2008, of which 20 are currently active. The pipeline spans early- to late-stage development, comprising 7 Phase 1, 9 Phase 2, and 8 Phase 3 trials. CSPC Megalith's research is heavily concentrated in a single therapeutic area, with Oncology programs accounting for 95% of active trials. Within Oncology, the company is pursuing multiple indications, with a particular emphasis on Solid Tumor (Advanced) with 6 active trials, followed by Non-Small Cell Lung Cancer (NSCLC) with 4 active trials, Bladder Cancer with 2 active trials, Breast Cancer with 2 active trials, and Head and Neck Cancer with 2 active trials. The presence of multiple Phase 3 trials in NSCLC, Bladder Cancer and Breast Cancer suggests a potential for near-term clinical catalysts within the Oncology space.